Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.20 -2.2%	$1.92	$1.03 ▼ $2.64	$440.75M	1.47	1.74 million shs	963,664 shs
MBX MBX Biosciences	$10.75 -4.8%	$11.09	$4.81 ▼ $27.50	$359.31M	N/A	257,408 shs	1.14 million shs
PVLA Palvella Therapeutics	$22.08 +7.1%	$23.54	$6.20 ▼ $29.27	$244.21M	-0.1	136,637 shs	1.14 million shs
TELO Telomir Pharmaceuticals	$1.53 -10.0%	$2.21	$1.52 ▼ $8.40	$45.53M	-0.37	167,054 shs	2.25 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	-11.29%	-3.08%	+61.76%	+65.41%
MBX MBX Biosciences	0.00%	+10.37%	-14.21%	+45.66%	+1,074,999,900.00%
PVLA Palvella Therapeutics	0.00%	+0.14%	-9.14%	-21.11%	+2,207,999,900.00%
TELO Telomir Pharmaceuticals	0.00%	-13.07%	-21.54%	-52.63%	-68.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	2.9069 of 5 stars	3.7	3.0	2.5	1.7	0.6
MBX MBX Biosciences	2.8782 of 5 stars	3.5	0.0	2.3	3.3	0.6
PVLA Palvella Therapeutics	3.2702 of 5 stars	3.6	0.0	2.5	4.2	0.6
TELO Telomir Pharmaceuticals	2.9865 of 5 stars	3.8	2.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$8.67	293.94% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	248.84% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	109.63% Upside
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	880.39% Upside

Current Analyst Ratings Breakdown

Latest TELO, ATAI, MBX, and PVLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/10/2025	MBX MBX Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
4/10/2025	MBX MBX Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $44.00
4/10/2025	MBX MBX Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$38.00
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,421.77	N/A	N/A	$0.69 per share	3.19
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	$42.81M	5.70	N/A	N/A	$5.58 per share	3.96
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
TELO Telomir Pharmaceuticals	-$16.53M	-$0.42	N/A	N/A	N/A	N/A	-2,009.40%	-1,009.72%	8/12/2025 (Estimated)

Latest TELO, ATAI, MBX, and PVLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/12/2025	Q1 2025	TELO Telomir Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
MBX MBX Biosciences	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	8.84	8.84
TELO Telomir Pharmaceuticals	N/A	0.75	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
MBX MBX Biosciences	N/A
PVLA Palvella Therapeutics	40.11%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
MBX MBX Biosciences	52.19%
PVLA Palvella Therapeutics	20.50%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
TELO Telomir Pharmaceuticals	1	29.76 million	N/A	N/A

TELO, ATAI, MBX, and PVLA Headlines

Recent News About These Companies

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025 | accessnewswire.comA

Telomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s disease

June 14, 2025 | pharmabiz.comP

TELO Rises on Promising Telomir-1 Preclinical Results

June 13, 2025 | insidermonkey.com

TELO Rises on Promising Telomir-1 Preclinical Results

June 13, 2025 | msn.com

TELO Continues Trend of Significant Trial Announcements

June 11, 2025 | msn.com

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

June 11, 2025 | accessnewswire.comA

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...

June 7, 2025 | usatoday.com

TELO Data Indicates Aging Reversal Potential

June 6, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

June 5, 2025 | accessnewswire.comA

Telomir announces positive preclinical data for its novel oral AMD therapeutic

June 3, 2025 | ophthalmologytimes.comO

Telomir Pharmaceuticals Joins BIO Convention for Partnerships

June 2, 2025 | tipranks.com

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

June 2, 2025 | accessnewswire.comA

Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA ...

May 29, 2025 | finanznachrichten.de

TELO Produces Results with Exciting AMD Implications

May 29, 2025 | msn.com

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 29, 2025 | accessnewswire.comA

Telomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual Separation

May 21, 2025 | marketwatch.com

Telomir Pharmaceuticals Appoints New Chief Financial Officer

May 21, 2025 | tipranks.com

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 21, 2025 | accessnewswire.comA

Telomir Pharmaceuticals

May 19, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, ATAI, MBX, and PVLA Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.20 -0.05 (-2.22%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.22 +0.02 (+1.09%)

As of 05:31 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

MBX Biosciences NYSE:MBX

$10.75 -0.54 (-4.78%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.88 -0.87 (-8.09%)

As of 04:00 AM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Palvella Therapeutics NASDAQ:PVLA

$22.08 +1.46 (+7.08%)

As of 06/27/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Telomir Pharmaceuticals NASDAQ:TELO

$1.53 -0.17 (-10.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.74 +0.21 (+13.40%)

As of 04:05 AM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time